Clinical evidence is becoming more coordinated. Reimbursement is not. Europe is often described as one of the great prizes for high-risk MedTech and IVD companies. In one sense, that is …

For many MedTech, IVD, digital health, biotech and pharmaceutical companies, the difficult question is no longer simply whether a technology can reach the market. Regulatory approval remains essential. A CE …

Why the best first market is not the biggest one, but the place where value becomes visible fastest Ask a MedTech, IVD, AI or digital health company where it wants …

Reframing endometriosis Endometriosis has traditionally been described as a chronic gynaecological condition characterised by the presence of endometrial-like tissue outside the uterus.¹ Its most recognised symptoms include dysmenorrhoea, chronic pelvic …

Medical purpose, MiGeL and price discipline From 1 July 2026, Switzerland will introduce reimbursement for selected medical-purpose digital health applications through MiGeL/LiMA. This article explains how companies should approach Swiss …

Price Follows the Patient Pathway Healthcare companies often begin their pricing story in the wrong place. They start with the product. They describe the device, the assay, the implant, the …